AAPG
Ascentage Pharma Group InternationalNASDAQHEALTHCAREBIOTECHNOLOGY
Key Statistics
Market Cap
$1.60B
P/E Ratio
—
EPS
$-2.06
Beta
0.65
52W High
$48.45
52W Low
$16.92
50-Day MA
$22.18
200-Day MA
$28.46
Dividend Yield
—
Profit Margin
-216.50%
Forward P/E
—
PEG Ratio
—
About Ascentage Pharma Group International
Ascentage Pharma Group International, a clinical-stage biotechnology company, develops therapies for cancers, chronic hepatitis B virus (HBV), and age-related diseases in Mainland China. The company is headquartered in Suzhou, China.
Fundamentals
| Revenue (TTM) | $574.12M |
| Gross Profit (TTM) | $525.18M |
| EBITDA | $-1.14B |
| Operating Margin | -193.30% |
| Return on Equity | -154.60% |
| Return on Assets | -23.00% |
| Revenue/Share (TTM) | $6.45 |
| Book Value | $2.11 |
| Price-to-Book | 8.16 |
| Price-to-Sales (TTM) | 2.78 |
| EV/Revenue | 18.03 |
| EV/EBITDA | — |
| Quarterly Earnings Growth (YoY) | 0.00% |
| Quarterly Revenue Growth (YoY) | 117.00% |
| Shares Outstanding | $93.34M |
| Float | $55.71M |
| % Insiders | 0.00% |
| % Institutions | 0.06% |
Historical Volatility
HV 10-Day
46.80%
HV 20-Day
54.41%
HV 30-Day
50.36%
HV 60-Day
74.61%
HV Rank
29.8%
Volatility is currently contracting
Analyst Ratings
Consensus ($47.56 target)
2
Strong Buy6
BuyMore HEALTHCARE Stocks
Data last updated: 6/13/2026